

U.S.S.N. 09/800,855  
FILED March 7, 2001  
AMENDMENT

3. (amended) The method of claim 2, wherein [said] the COX-1 inhibitor is indomethacin or flurbiprofin.

4. (amended) The method of claim 1, [wherein the first agent is an] comprising administering an inflammatory cytokine inhibitor selected from the group consisting of an IL-6 inhibitor, a TNF-alpha inhibitor, an IL-1 inhibitor, and an interferon-gamma inhibitor.

5. (amended) The method of claim 4 wherein the [first agent] inflammatory cytokine inhibitor is a TNF-alpha inhibitor [and the second agent is an MMP inhibitor].

6. (amended) The method of claim 1 wherein [said] the MMP inhibitor is a tetracycline.

7. (amended) The method of claim 6 wherein [said] the tetracycline is minocycline.

Please cancel claims 8 and 9.

10. The method of claim [1] 5 wherein the TNF-alpha inhibitor is thalidomide.

11. (amended) The method of claim 1 [wherein the first agent is] comprising administering a mast cell inhibitor selected from the group consisting of an antihistamine, a serine protease inhibitor, and a degranulation inhibitor.

12. (amended) The method of claim 1 wherein the [first and second agents] NSAID, inflammatory cytokine inhibitor, or mast cell inhibitor and MMP inhibitor are provided mixed together in a composition.

Please cancel claims 15-22.

23. (amended) The method of claim 22, wherein [said] the mucositis is induced by chemotherapy.

24. (amended) The method of claim 22, wherein [said] the mucositis is induced by radiation therapy.